A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations.
Cost-effectiveness
Cost-utility
Systematic Review
Testing
Tuberculosis
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
05 Oct 2022
05 Oct 2022
Historique:
received:
28
04
2022
accepted:
05
09
2022
entrez:
5
10
2022
pubmed:
6
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
The World Health Organisation (WHO) recommends that testing and treatment for latent tuberculosis infection (LTBI) should be undertaken in high-risk groups using either interferon gamma release assays (IGRAs) or a tuberculin skin test (TST). As IGRAs are more expensive than TST, an assessment of the cost-effectiveness of IGRAs can guide decision makers on the most appropriate choice of test for different high-risk populations. This current review aimed to provide the most up to date evidence on the cost-effectiveness evidence on LTBI testing in high-risk groups-specifically evidence reporting the costs per QALY of different testing strategies. A comprehensive search of databases including MEDLINE, EMBASE and NHS-EED was undertaken from 2011 up to March 2021. Studies were screened and extracted by two independent reviewers. The study quality was assessed using the Bias in Economic Evaluation Checklist (ECOBIAS). A narrative synthesis of the included studies was undertaken. Thirty-two studies reported in thirty-three documents were included in this review. Quality of included studies was generally high, although there was a weakness across all studies referencing sources correctly and/or justifying choices of parameter values chosen or assumptions where parameter values were not available. Inclusions of IGRAs in testing strategies was consistently found across studies to be cost-effective but this result was sensitive to underlying LTBI prevalence rates. While some concerns remain about uncertainty in parameter values used across included studies, the evidence base since 2010 has grown with modelling approaches addressing the weakness pointed out in previous reviews but still reaching the same conclusion that IGRAs are likely to be cost-effective in high-income countries for high-risk populations. Evidence is also required on the cost-effectiveness of different strategies in low to middle income countries and countries with high TB burden.
Sections du résumé
BACKGROUND
BACKGROUND
The World Health Organisation (WHO) recommends that testing and treatment for latent tuberculosis infection (LTBI) should be undertaken in high-risk groups using either interferon gamma release assays (IGRAs) or a tuberculin skin test (TST). As IGRAs are more expensive than TST, an assessment of the cost-effectiveness of IGRAs can guide decision makers on the most appropriate choice of test for different high-risk populations. This current review aimed to provide the most up to date evidence on the cost-effectiveness evidence on LTBI testing in high-risk groups-specifically evidence reporting the costs per QALY of different testing strategies.
METHODS
METHODS
A comprehensive search of databases including MEDLINE, EMBASE and NHS-EED was undertaken from 2011 up to March 2021. Studies were screened and extracted by two independent reviewers. The study quality was assessed using the Bias in Economic Evaluation Checklist (ECOBIAS). A narrative synthesis of the included studies was undertaken.
RESULTS
RESULTS
Thirty-two studies reported in thirty-three documents were included in this review. Quality of included studies was generally high, although there was a weakness across all studies referencing sources correctly and/or justifying choices of parameter values chosen or assumptions where parameter values were not available. Inclusions of IGRAs in testing strategies was consistently found across studies to be cost-effective but this result was sensitive to underlying LTBI prevalence rates.
CONCLUSION
CONCLUSIONS
While some concerns remain about uncertainty in parameter values used across included studies, the evidence base since 2010 has grown with modelling approaches addressing the weakness pointed out in previous reviews but still reaching the same conclusion that IGRAs are likely to be cost-effective in high-income countries for high-risk populations. Evidence is also required on the cost-effectiveness of different strategies in low to middle income countries and countries with high TB burden.
Identifiants
pubmed: 36199061
doi: 10.1186/s12890-022-02149-x
pii: 10.1186/s12890-022-02149-x
pmc: PMC9533619
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
375Informations de copyright
© 2022. The Author(s).
Références
Clin Infect Dis. 2021 Nov 2;73(9):e3476-e3482
pubmed: 32584968
BMC Health Serv Res. 2011 Sep 30;11:247
pubmed: 21961888
Eur Respir J. 2015 Jul;46(1):165-74
pubmed: 25882810
Int J Infect Dis. 2020 Mar;92S:S72-S77
pubmed: 32171953
PLoS One. 2019 Apr 9;14(4):e0214532
pubmed: 30964878
Tuberculosis (Edinb). 2016 Jul;99:81-91
pubmed: 27450009
Travel Med Infect Dis. 2016 Sep - Oct;14(5):489-498
pubmed: 27238907
J Hosp Infect. 2011 Jun;78(2):152-4
pubmed: 21440954
Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):513-23
pubmed: 26588001
Health Technol Assess. 2016 May;20(38):1-678
pubmed: 27220068
Mol Diagn Ther. 2012 Jun 1;16(3):181-90
pubmed: 22594558
Eur Respir J. 2011 Jan;37(1):88-99
pubmed: 21030451
JAMA Intern Med. 2017 Dec 1;177(12):1755-1764
pubmed: 29049814
Am J Respir Crit Care Med. 2011 Sep 1;184(5):590-601
pubmed: 21562129
Value Health. 2016 Mar-Apr;19(2):267-76
pubmed: 27021762
Dig Dis Sci. 2014 Mar;59(3):554-63
pubmed: 23949640
Emerg Infect Dis. 2019 Apr;25(4):661-671
pubmed: 30882302
Am J Kidney Dis. 2019 Jan;73(1):39-50
pubmed: 30269868
Epidemiol Infect. 2016 Nov;144(15):3215-3225
pubmed: 27412626
Epidemiol Infect. 2013 Oct;141(10):2224-34
pubmed: 23286364
Infect Control Hosp Epidemiol. 2019 Mar;40(3):341-349
pubmed: 30786941
J Hosp Infect. 2015 Feb;89(2):99-108
pubmed: 25559158
J Infect. 2019 Jan;78(1):58-65
pubmed: 30009853
Eur Respir J. 2015 Apr;45(4):928-52
pubmed: 25792630
Health Technol Assess. 2018 Oct;22(56):1-96
pubmed: 30334521
J Infect. 2014 Jan;68(1):32-42
pubmed: 23973660
PLoS One. 2017 Oct 30;12(10):e0186778
pubmed: 29084227
Int J Tuberc Lung Dis. 2017 Sep 1;21(9):965-976
pubmed: 28826445
J Infect. 2020 Aug;81(2):289-296
pubmed: 32473234
Am J Kidney Dis. 2013 Jan;61(1):22-32
pubmed: 22784996
BMJ Open. 2012 Mar 01;2(2):e000630
pubmed: 22382118
PLoS One. 2018 Jan 2;13(1):e0189531
pubmed: 29293514
Chest. 2010 Apr;137(4):952-68
pubmed: 20022968
Int J Tuberc Lung Dis. 2015 Jul;19(7):857-63
pubmed: 26056114